Stimulating the development of orphan (and other) vaccines.

por Schwartz, B, Rabinovich, N R
Publicado 1999

The role of tacit knowledge in communication and decision-making during emerging public health incidents

por Sanford, S., Schwartz, B., Khan, Y.
Publicado 2020

Butyrate regulates E-cadherin transcription, isoform expression and intracellular position in colon cancer cells

por Barshishat, M, Polak-Charcon, S, Schwartz, B
Publicado 2000

Butyrate down-regulates CD44 transcription and liver colonisation in a highly metastatic human colon carcinoma cell line

por Barshishat, M, Levi, I, Benharroch, D, Schwartz, B
Publicado 2002

Analytic modeling of neural tissue: II. Nonlinear membrane dynamics

por Schwartz, B. L., Brown, S. M., Muthuswamy, J., Sadleir, R. J.
Publicado 2022

Characterization of toxicokinetics and toxicodynamics with linear systems theory: application to lead-associated cognitive decline.

por Links, J M, Schwartz, B S, Simon, D, Bandeen-Roche, K, Stewart, W F
Publicado 2001

Associations of tibial lead levels with BsmI polymorphisms in the vitamin D receptor in former organolead manufacturing workers.

por Schwartz, B S, Stewart, W F, Kelsey, K T, Simon, D, Park, S, Links, J M, Todd, A C
Publicado 2000

Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with polymorphisms in the vitamin D receptor and [delta]-aminolevulinic acid dehydratase genes.

por Schwartz, B S, Lee, B K, Lee, G S, Stewart, W F, Simon, D, Kelsey, K, Todd, A C
Publicado 2000

Mice with Dab1 or Vldlr insufficiency exhibit abnormal neonatal vocalization patterns

por Fraley, E. R., Burkett, Z. D., Day, N. F., Schwartz, B. A., Phelps, P. E., White, S. A.
Publicado 2016

Associations of blood pressure and hypertension with lead dose measures and polymorphisms in the vitamin D receptor and delta-aminolevulinic acid dehydratase genes.

por Lee, B K, Lee, G S, Stewart, W F, Ahn, K D, Simon, D, Kelsey, K T, Todd, A C, Schwartz, B S
Publicado 2001

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

por Awada, A, Hendlisz, A, Gil, T, Bartholomeus, S, Mano, M, de Valeriola, D, Strumberg, D, Brendel, E, Haase, C G, Schwartz, B, Piccart, M
Publicado 2005

Detection of malignancy-associated metabolites in the sera of cancer patients by electron capture gas chromatography.

por Brooks, J. B., Almenoff, P. L., Daneshvar, M. I., Johnson, A. H., Spechart, V. J., Basta, M. T., Unger, S. E., King, J. N., Schwartz, B.
Publicado 1994

Association of community types and features in a case–control analysis of new onset type 2 diabetes across a diverse geography in Pennsylvania

por Schwartz, B S, Pollak, Jonathan, Poulsen, Melissa N, Bandeen-Roche, Karen, Moon, Katherine, DeWalle, Joseph, Siegel, Karen, Mercado, Carla, Imperatore, Giuseppina, Hirsch, Annemarie G
Publicado 2021

Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy.

por Kelsey, K. T., Ross, D., Traver, R. D., Christiani, D. C., Zuo, Z. F., Spitz, M. R., Wang, M., Xu, X., Lee, B. K., Schwartz, B. S., Wiencke, J. K.
Publicado 1997

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis

por Santoro, A, Simonelli, M, Rodriguez-Lope, C, Zucali, P, Camacho, L H, Granito, A, Senzer, N, Rimassa, L, Abbadessa, G, Schwartz, B, Lamar, M, Savage, R E, Bruix, J
Publicado 2013

emm typing and validation of provisional M types for group A streptococci.

por Facklam, R, Beall, B, Efstratiou, A, Fischetti, V, Johnson, D, Kaplan, E, Kriz, P, Lovgren, M, Martin, D, Schwartz, B, Totolian, A, Bessen, D, Hollingshead, S, Rubin, F, Scott, J, Tyrrell, G
Publicado 1999

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

por Eisen, T, Ahmad, T, Flaherty, K T, Gore, M, Kaye, S, Marais, R, Gibbens, I, Hackett, S, James, M, Schuchter, L M, Nathanson, K L, Xia, C, Simantov, R, Schwartz, B, Poulin-Costello, M, O'Dwyer, P J, Ratain, M J
Publicado 2006

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

por Papadopoulos, K P, El-Rayes, B F, Tolcher, A W, Patnaik, A, Rasco, D W, Harvey, R D, LoRusso, P M, Sachdev, J C, Abbadessa, G, Savage, R E, Hall, T, Schwartz, B, Wang, Y, Kazakin, J, Shaib, W L
Publicado 2017

In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)

por Ranieri, C., Di Tommaso, S., Loconte, D. C., Grossi, V., Sanese, P., Bagnulo, R., Susca, F. C., Forte, G., Peserico, A., De Luisi, A., Bartuli, A., Selicorni, A., Melis, D., Lerone, M., Praticò, A. D., Abbadessa, G., Yu, Y., Schwartz, B., Ruggieri, Martino, Simone, Cristiano, Resta, Nicoletta
Publicado 2018

The pp --> pp$\eta$ reaction near the kinematical threshold

por Calén, H, Carius, S, Fransson, K, Gustafsson, L, Häggström, S, Höistad, Bo, Johansson, A, Johansson, T, Kullander, Sven, Moehn, J, Mörtsell, A, Ruber, Roger J M Y, Schuberth, U, Zlomanczuk, Yu, Ekström, C, Kilian, K, Oelert, Walter, Sefzick, T, Waters, M, Bondar, A E, Kuzmin, A, Schwartz, B, Sidorov, V, Kupsc, A, Stepaniak, J, Morosov, B, Povtorejko, A A, Sukhanov, A, Zabierowski, J, Wilhelmi, Z
Publicado 1995